anti-inflammatory

why it works

Four items, four different places on the cascade.

Oral KPV is the C-terminal tripeptide of alpha-MSH. It carries the anti-inflammatory activity of the parent without the pigmentation or broader melanocortin effects, and the oral route is chosen deliberately because it reaches the intestinal epithelium where the local action is wanted.

⚠️ WITH NALTREXONE THE DOSE IS THE MECHANISM AND THIS IS NOT A DETAIL. At the low dose the proposal is transient opioid receptor blockade driving endorphin rebound, plus TLR4 antagonism on microglia. At ordinary naltrexone doses none of that applies and it is simply an opioid antagonist, which is a completely different drug doing a completely different thing. A reader who takes the wrong amount does not get a weaker version of this; they get something else.

Astaxanthin is a xanthophyll carotenoid that sits within the membrane rather than in cytosol, which is why it is described as protecting lipids specifically. There is real human data on oxidative markers and thinner data on clinical outcomes.

Emoxypine succinate also appears in the neuroprotection stack, and reusing it across two is deliberate rather than lazy: antioxidant activity plus mitochondrial support, with the succinate half acting as a Krebs cycle substrate in its own right.

how they work together

Four different points on the inflammatory cascade, which is the whole argument: a peptide acting locally in the gut, a receptor-level immune modulator, a membrane antioxidant and a mitochondrial one.

Oral KPV acts at the epithelium. It is the C-terminal tripeptide of alpha-MSH, carrying the anti-inflammatory activity without the pigmentation or melanocortin effects of the parent peptide, and given orally it reaches the intestinal epithelium directly. That local action is the reason the route is specified rather than incidental.

Low-dose naltrexone acts centrally and at the microglia. The proposed mechanism is transient opioid receptor blockade driving an endorphin rebound, plus TLR4 antagonism on microglia, which is where the neuroinflammatory rationale comes from.

Astaxanthin and emoxypine both address oxidative contributions but in different compartments: astaxanthin spans the lipid membrane, emoxypine supports mitochondrial function and its succinate half is itself a Krebs cycle substrate.

Local, receptor-level, membrane and mitochondrial. Four compartments, minimal overlap.

what it feels like

⚠️ THIS IS A DAMPING STACK AND IT SHOULD NOT FEEL LIKE MUCH DAY TO DAY, which is worth saying because the alternative is someone escalating in search of a sensation.

Low-dose naltrexone's most commonly reported acute effect is on sleep and dreams, which is why it is usually taken at night, and that effect frequently settles over the first weeks.

Where people do report change it is over weeks and is described as a reduction in background symptoms rather than an event: less stiffness, fewer flares, less gut reactivity. That is a difficult signal to read and is worth tracking in writing rather than by memory.